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Virtual and high-throughput screens (HTS) should have complementary strengths and weaknesses, but
studies that prospectively and comprehensively compare them are rare. We undertook a parallel
docking and HTS screen of 197861 compounds against cruzain, a thiol protease target for Chagas
disease, looking for reversible, competitive inhibitors. On workup, 99% of the hits were eliminated as
falsepositives,yielding146well-behaved,competitiveligands.Thesefellintofivechemotypes:twowere
prioritized by scoring among the top 0.1% of the docking-ranked library, two were prioritized by
behavior in the HTS and by clustering, and one chemotype was prioritized by both approaches.
Determinationofaninhibitor/cruzaincrystalstructureandcomparisonofthehigh-scoringdockinghits
to experiment illuminated the origins of docking false-negatives and false-positives. Prioritizing
molecules that are both predicted by docking and are HTS-active yields well-behaved molecules,
relatively unobscured by the false-positives to which both techniques are individually prone.
Introduction
Both structure-based (docking) and HTS
a campaigns can
evaluate millions of compounds as potential lead ligands for
drugdiscoveryand,increasingly,chemicalbiology.
1,2Whereas
all compounds are tested in an HTS campaign, only a few
prioritized compounds are experimentally tested in a docking
campaign.Dockingissubjecttowell-knownproblems,includ-
ing under-sampling protein and ligand configurations and
the use of approximate scoring functions, and may thus miss
many ligands. Conversely, most HTS hits are typically arti-
facts or problematic compounds, and winnowing these down
to the few truly interesting active molecules demands much
effort.
Itisconceivablethatthetwotechniquesmightcomplement
eachother.Docking’s weaknesses
3 are orthogonaltothoseof
HTS, and one might expect that molecules that both fit well
into a protein structure, as revealed by docking, and that are
active in an HTS campaign, may be the best to prioritize for
initial consideration. If that is the case, one could imagine a
combined approach that would dramatically increase the
compoundsavailableforevaluationtodockingwhileimprov-
ingone’sabilitytorapidlyprioritizehitsfromHTS.However,
it remains uncertain whether such an approach is pragmatic.
Whereas there have been several comparisons of hit rates
between docking and HTS,
4-9 only rarely has this been done
on exactly the same compounds
4,6 and only once have the
mechanism of action of all hits been evaluated.
4,10 This last
study, although revealing, involved a relatively small library
of compounds (70000) and found no true reversible hits by
HTS, vitiating a full evaluation of the docking screen.
We therefore wished to comprehensively compare a dock-
ing and HTS campaign against exactly the same compounds
and exactly the same target, systematically analyzing the
mechanism of action of all active molecules and identifying
those that were specific, novel, and competitive. A 197861-
compoundlibrarywasscreenedagainsttheX-raystructureof
the thiol protease cruzain, a key drug target for Chagas’
disease,
11 using docking. Subsequently, the same library was
screenedbyquantitativeHTS(qHTS)
12againstthisenzymein
a biochemical assay. Each compound was screened in seven
point dose-response, varying from 3.7 nM to 57.5 μM, with
screening statistics that supported the reliability of the screen
(e.g., the Z0 for the detergent free and detergent-present
screens were 0.78 and 0.93, respectively).
13 To control for
one of the major mechanisms of artifactual inhibition, all
compoundsatallconcentrationswerecounter-screenedinthe
presence of a nonionic detergent, and active molecules were
subsequentlytestedinasecondarycounter-screenforpromis-
cuous covalent inhibition. All active molecules that remained
were subsequently evaluated in detailed cheminformatics and
mechanistic studies, ultimately including protein crystallo-
graphy; the results of these evaluations are presented within.
Thisstudyenablesustoposethefollowingquestions.First,
what are the HTS and the docking false positives, and what
aretheirmechanisticbases?Understandingthesemechanisms
is useful in itself, and a comprehensive analysis of them, on a
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largescale,hasfewprecedents.Doingsoisessentialtomeaning-
fullycomparestructure-basedandhigh-throughputscreening.
Second,whatarethedockingfalsenegativesandwhyarethey
missed? Because we can crystallize at least some of the new
ligands with cruzain, we can investigate this question at
atomic resolution. Third, can novel and reversible inhibitors
be discovered for cruzain, a target that has, until now, been
dominated by irreversible, covalent molecules?
11,14 Finally,
can docking reliably prioritize the true inhibitors among its
very top-ranked molecules? If docking can prioritize hits to
testfromscreening,providingastructuralmodelthatbolsters
the HTS readoutwhile remaining orthogonal toit, it suggests
a general method to combine the two techniques to their
mutual benefit.
Results
Database Ranking by Docking. Prior to experimentally
screening the MLSMR by qHTS, the exact same library was
docked against a crystal structure of cruzain (PDB code
1AIM
15). Waters and ligands were removed from the struc-
ture. The MLSMR library was prepared according to the
ZINC
16 database protocols and screened using DOCK
3.5.54.
17,18 The cruzain structure was kept rigid, and ligand
flexibility was considered by docking a precalculated data-
base of conformations for each compound. Each small
molecule was evaluated in up to 600 conformations, in an
average of 18735 orientations (over 10 million configura-
tions per molecule), and scored by van der Waals and
electrostatics complementarity, using AMBER and DelPhi
derived potentials, respectively, corrected for ligand desol-
vation. The best scoring pose for any given molecule was
used for ranking the database.
Preliminary Characterization of HTS Hits. We previously
characterized those molecules from the qHTS that could be
rapidly identified as artifacts.
13 Two screens were run in
parallel, one in the presence of 0.01% Triton X-100 and one
without detergent. All other conditions were maintained
except that the enzyme concentration was 2-fold higher in
the nondetergent screen owing to the reduced activity of
cruzain in the absence of detergent. In the discussion that
follows, we use the term “hit” contingently, beginning most
permissively, so as to reduce false negatives, and with
increasing stringency as we seek to remove false positives.
“Hits” were initially defined as those compounds that
showed over 40% inhibition at the highest concentration
assayed. By this criterion, over 16000 hits, representing
approximately 8%ofthewhole library,wereobserved.Such
high hit rate is not in itself credible, and our first task was to
understand the origins of these molecules and winnow them
down. Close to 90% were removed based on detergent-
sensitiveactivity;thatis,theyinhibitedstrongly inthescreen
that lacked detergent but inhibited substantially less, and
with less well-defined dose-response curves, in the screen
that included detergent. This effectively reduced the appa-
rent hit rate toabout 0.8%, a level frequently encountered in
screening. Another 3% of the apparent inhibitors were
fluorescent artifacts.
19 Finally, the dose-response curves
inherent in qHTS allowed us to reduce this number by
insisting that compounds show a dose-response, and not
be the product of capricious inhibition at the highest con-
centration, with at least 80% inhibition at the highest con-
centrationtested.Thiseliminatedanother3%ofhitsasweak
inhibitors (Table 1), leaving us with 921 “hits” (6% of the
original apparent “inhibitors”, 0.46% of the MLSMR). Of
these, 493 were “filtered inhibitors”,
13 here we decided to
pursue all 921 compounds that had not been removed as
screening artifacts in the initial, high-throughput tests.
Characterization of these 921 compounds for detailed
mechanism, andcomparisontothedockingresults,wasthus
the point of departure for this study. We adopted two
parallel tracks, one investigating the mechanism of com-
poundsactivebyqHTSandthathadhighdockingranks,the
second one pursuing compounds based on chemotype clus-
tering and behavior in the initial qHTS. Initial testing of
compounds prioritized by docking was conducted at UCSF,
while initial testing of representative cluster compounds was
initially conducted at the NCGC. Whereas there was some
overlap among the compounds prioritized by the two crite-
ria, there were also a substantial number of compounds that
were unique to each track. All compounds that were ulti-
mately deemed to be competitive and reversible inhibitors
were subject to the same battery of confirmatory experi-
ments.
Prioritization ofHTSFollowupBasedonDockingResults.
We began the follow up of the remaining 921 qHTS actives
by investigating those among the top ranking 1% com-
pounds by docking. Thirty-four of these ranked among the
top 1% of compounds by docking score, 19 of which could
easily be resourced from vendors. These were tested in a
series of low throughput assays to probe their mechanism of
action. To investigate whether they were time-dependent, a
hallmark of covalent-acting molecules, cruzain inhibition
after 10 min preincubation with an inhibitor was compared
to activity without preincubation. Two compounds showed
time-dependence (Supporting Information Table S1).
Next the compounds were evaluated for colloidal aggre-
gation in a greater detail. Even though these compounds
were not detergent-sensitive in the qHTS, as usually ob-
served for this class of artifacts, some aggregators can still
inhibitenzymesin0.01%TritonX-100,andsometimes0.1%
Table 1. Sources of Actives in qHTS and Docking Screen
qHTS virtual screening
16221 hits (100%) 198 top ranking compounds (100%)
false positives 16078 (99.1%) false positives 193 (97.5%)
aggregators 14243 (87.8%) conformer focusing 106 (53.5%)
detergent-resistant nonselective 745 (4.6%) high internal energy conformations 101 (51.0%)
floppy compounds 5 (2.5%)
detergent-resistant weak 550 (3.4%) high molecular weight, unfulfilled polar groups 68 (34.3%)
detergent-resistant fluorescent 507 (3.1%) others 19 (9.6%)
others 33 (0.2%)
noncovalent competitive 146 (0.9%) noncovalent competitive 5 (2.5%)
substrates 88 (0.54%) substrates 3 (1.5%)
inhibitors 58 (0.36%) inhibitors 2 (1.0%)Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 4893
of this detergent is required to prevent the nonspecific
inhibition.
4 On the basis of comparison of the levels of
cruzain inhibition by these compounds in three different
Triton concentrations (no Triton, 0.01% and 0.1%), three
compounds were classified as detergent-sensitive, likely ac-
tive via colloidal aggregation, and were therefore discarded
fromfurtherconsideration.Thecompoundswerealsotested
against AmpC β-lactamase, an unrelated enzyme, as a con-
trol for promiscuous inhibition, and two additional com-
pounds inhibited this enzyme at concentrations inhibitory
for cruzain.
This left 11 compounds that showed no detergent sensiti-
vity, noAmpC inhibition, and no time-dependence (Table 2).
Except for compounds 4 and 5, all others can be clustered
basedontheir2Dstructure,andwillbereferredtoasCluster
1 from now on. The mechanism of inhibition was evaluated
for one compound from each of these chemical classes, and
these three scaffolds were confirmed as pure competitive
inhibitors. In Cluster 1, the best scoring compound ranked 6
outof197861bydocking,andthemost potentcompoundof
thisclass,withaKi=65nM,ranked789.Compounds4and5,
withKivaluesof1.6and6μM,ranked153and173outofthe
over 197000 compounds docked. Three close analogues of
compound 4 were indentified among the qHTS hits. These
were also retested and confirmed as inhibitors. The most
potent compound in this cluster was shown to be competi-
tive and slightly more potent than 4, with a Ki of 0.8 μM
(Supporting Information Table S2, Figure 1). Thus, each of
these three classes had representatives among the 198 top
scoring compounds (top 0.1% of the dock ranked library).
Characterization of HTS Hits Based on Chemotypes. In
parallel with testing compounds that scored well by docking
and were active in the qHTS, we sought compounds based
purely on qHTS activity that represented major chemotypes
of hits; the two ways of prioritizing compounds were kept
intentionally separate. A combination of cheminforma-
tics analysis and enzymological characterization was used.
Visual inspection of the structures of the most active, non-
fluorescent, detergent-insensitive actives suggested that many
were electrophilic and thus possibly subject to attack by the
nucleophilic cruzain. To facilitate identification of covalent
inhibitors, these compounds were clustered based on their
2D structure and representatives from each cluster were
counter-screened against papain, a cysteine protease whose
substratespecificity differs fromthatofcruzain.The 921top
screening “hits” were represented by 199 compounds, corre-
sponding to 47 clusters and 35 singletons; it was these 199
that were counter-screened. Of these, 167 compounds repre-
senting 38 clusters and 32 singletons had little or no specifi-
city for cruzain over papain, consistent with a nonspecific
Table 2. qHTS Hits Prioritized for Follow up Based on Their Ranking among Top 1% of Dock Ranked Database and Confirmed As Competitive
Inhibitors4894 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 Ferreira et al.
covalent mechanism of action. Whereas papain inhibition is
not definitive proof of such a mechanism, inspection of the
chemical structures of these inhibitors supports that view,
as they are characterized by Michael acceptors, R-halo-
carbonyls, and other activated electrophiles known to target
sulfhydryl proteases (Figure 1a).
20 This left us with nine
clusters and three singletons that were selective for cruzain
over papain, including Cluster 1 that had been, in parallel,
testedbasedonprioritizationinthedockingscreen.Expand-
ingbackthenineclusterstoalltheMLSMRcompoundsthat
they represented, and that showed good dose-response
curves in the qHTS, led to a total of 173 compounds from
the full screen; these clusters in addition to the three single-
tons gave a cumulative total of 176 compounds as potential
inhibitors forfollow-up. Wenote thatanotherclassofactive
molecules identified at this stage, the triazine nitriles, was
also pursued. These molecules act by a covalent mechanism,
and so were missed by docking, which only considers non-
covalent complementarity. Because these molecules have
been discussed previously,
21 they will not be further con-
sidered here.
Among the 12 classes of compounds selective for cruzain,
compounds from cluster 1 had been shown to be competi-
tive inhibitors (above). As with the tests of qHTS “hits”
Figure 1. Compounds representative of clusters active against papain (a) and of clusters of compounds selective for cruzain and followed up
after the papain counter-screen: (b) time-dependent, (c) detergent-sensitive, and (d) weak or irreproducible cruzain inhibitors.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 4895
prioritized by their docking rank (above), the remaining 11
compound clusters were tested for time-dependence, deter-
gent-sensitivity, promiscuous inhibition, and mode of inhi-
bition. Five of these 11 classes of molecules were found to be
time-dependent(Figure1b,SupportingInformationTableS3).
Of these, three were Michael acceptors and one was an
activated thiol ether, chemotypes that one might expect to
be reactive against cruzain’s activated thiol nucleophile. We
inferred that these five clusters, representing 16 of the 176
compounds (Supporting Information Table S3), were cova-
lent-acting inhibitors and so they were not further pursued.
Of the remaining six scaffolds, two apparently selective che-
mical classes were classified as detergent-sensitive, at the
higher detergent concentration, and discarded (Figure 1c).
For two of the four chemical classes that were neither time-
dependent nor detergent-sensitive, inhibition was weak or
not observed on detailed replication, including resourcing
the compound from vendors; these were also discounted
(Figure 1d). The remaining two classes were tested against
AmpC β-lactamase and did not inhibit this enzyme (Sup-
porting Information Table S3). Finally, these compounds
were tested at several substrate and compound concentra-
tions and confirmed as reversible, competitive inhibitors
(Supporting Information Figure 1), with Ki of 2 μM in both
cases (Table 3). Because these two chemical scaffolds were
not represented among the top ranking 0.1% or even among
the top 1% of the dock ranked database, these classes are
docking false negatives.
In summary, after detailed testing, five classes of com-
pounds, representing 146 compounds and 0.07% of the
library, were identified as competitive, reversible ligands
for cruzain (Table 3, Supporting Information Figure 1).
Table 3. Scaffolds of Cruzain Competitive Ligands
aThis class of ligand is recognized as a substrate of cruzain; all others are inhibitors.4896 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 Ferreira et al.
Ofthesefive,twowereidentifiedonlybythechemotype-based
follow-up pursued without reference to docking rank; these
two classes are docking false negatives. Correspondingly,
another two of the five classes were only pursued because
they had, in fact, high docking ranks. It was not pragmatic to
follow up each of the 921 “hits” in the papain counter-screen,
andsomecompoundswerenecessarilyleftout:thesetwo,one
of which represents a cluster of only four compounds and the
other which is a singleton, were among them. Whereas they are
certainly not screening false negatives, as they were active in
the qHTS, it is likely they would not have been prioritized for
follow up absent the docking results. Finally, a fifth cluster,
representing the vast majority of hits, was prioritized for
follow-up based both on high docking rankings and chemo-
type clustering (Figure 2). In total, these 146 compounds
represent 1% of all the initial “hits” and 13% of the deter-
gent-resistant counter-screened hits.
Search for HTS False Negatives. When combined with
HTS, virtual screening may not only prioritize HTS hits, but
in principle it can also illuminate HTS false negatives.
Indeed, in a docking and HTS campaign against β-lacta-
mase,thedockingscreenidentifiedjustsuchfalsenegatives.
4
To search for possible HTS false negatives for cruzain, we
therefore repurchased and retested compounds inactive in
the qHTS that had good complementarity to cruzain by
docking. Ultimately, 32 such compounds were selected and
retested. Among these, eight inhibited cruzain between 40
and 70% at 200 μM (Supporting Information Table S4).
However, further confirmation of these was complicated by
solubility limits. Whereas these compounds were neither
time-dependent nor detergent-sensitive, full establishment
of their mode of inhibition and reliability was not possible.
Given their weak activity, they were therefore disregarded;
no HTS false negatives were reliably identified despite sub-
stantial effort.
Comparison between Docking and HTS Results. To quan-
tifyDOCKperformanceinpredictingHTSresultsweturned
to enrichment factors, which compare the observed perfor-
mance to what would be expected if the database was
randomly ranked. A commonly used metric to evaluate
virtual screening, the enrichment factor is given by the ratio
between the percentage of ligands found in a chosen percen-
tage of the database and the percentage of the database
evaluated. For instance, if 100 known ligands are included
amongalargerlibraryofcompoundsdockedtoatarget,and
8% of the ligands rank in the top 1% of the overall database
ofcompounds,anenrichmentfactorof8isobtainedbecause
it is expected that only 1% of the ligands would be found by
randomselectioninthissliceofthedatabase.Thisisgivenby
the following formula:
EFð%Þ ¼
Nactiveð%Þ=Nactive
Nð%Þ=Ntotal
Where EF(%) is the enrichment factor at a chosen percen-
tage X of the database, Nactive(%) is the number of actives
ranked among the top X of the database, Nactive is the total
number of actives in library, N(%) is the total number of
Figure 2. Two parallel strategies employed in the follow up of qHTS hits. After removal of aggregators, fluorescent artifacts, and weak
inhibitors, the remaining HTS hits were followed up either based on docking prioritization or based on clustering by chemotypes.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 4897
compounds in X, and Ntotal is the total number of com-
pounds in the library.
On the basis of this metric, we observe a significant
improvement of DOCK performance as the HTS hits are
progressively winnowed and confirmed (Figure 3; see also
SupportingInformationFigure2forfullenrichmentcurves).
Here we focused on the top 0.1% of the database, or the 198
top-ranking compounds, which is to say the very top of the
ranked database. The initial enrichment factor, if all HTS
hits are considered as valid, is 3-fold over random selection.
As artifacts and covalent inhibitors are eliminated and we
progressively consider only nonaggregating, selective, and
competitive inhibitors, enrichment increases to 4-, 22-, and
34-fold. The largest increase is obtained when covalent
inhibitors are eliminated, reflecting the modeling of nonco-
valent complementarity in docking and its disregard for
reactivefunctionality.Theimprovementinenrichmentupon
eliminating aggregators is modest. This was initially unex-
pected, because one might imagine that this is an artifact
unique to HTS. However, the tendency to aggregate is
correlated with molecular weight, as is docking score, and
so docking also often enriches what are ultimately shown to
becolloidal aggregators(the originalmoleculesshown toact
by this mechanism were, in fact, discovered from a docking
screen
5,22).
Among the top 198 hits by DOCK ranking (0.1% of the
database), five competitive cruzain ligands were found, one
of them ranking sixth among all 197861 compounds. This
andanothertwocompounds,ranking120and197,belonged
to HTS cluster 1 (Table 3). The other two compounds
successfully predicted, 4 and 5, ranked 153 and 173, respec-
tively. These molecules represent three out of five competi-
tive scaffolds found by HTS. If we consider all hits which
ranked in the top 1% of the docking screen (i.e., top 1980
molecules), another 11 representatives of cluster 1 were
found, including the most potent cruzain inhibitor found in
this screen, compound 8, with a Ki of 65 nM and rank 789.
The other two scaffolds, clusters 2 and 31, scored poorly by
DOCK and are therefore considered here as false negatives,
with their bestscoring compounds respectively ranking7560
(3.8% of the database) and 31359 (15.9% of the database).
Thepredictedbindingmodesforthebestscoringcompounds
in each chemical class are shown in Figure 4. In most cases,
hydrogen bonds or dipole-dipole interactions are observed
to Gly66, Asp161, and Gln19, as previously observed in
published crystallographic complexes of cruzain bound to
other inhibitors.
23
Among the clusters of competitive ligands, cluster 44
showed the best enrichment, with its best scoring compound
(compound 4) ranking 153 and the worst scoring compound
ranking 21010 (10.6% of the database) (Supporting Infor-
mation Table S2, Figure 2b). Comparing the enrichment
curves for clusters 1, 2, and 31, it was surprising to observe
that virtual screening performed better for cluster 1, the
most flexible class of compounds (Supporting Information
Figure 2b). Within cluster 1, we investigated whether there
was any correlation between the relative ranking of the
molecules and their physical properties, especially the num-
berofrotatablebonds.However,forthepropertiesanalyzed
(number of rotatable bonds, molecular weight, xlogP, polar
surface area, number of H-bond donors or acceptors), no
trends were observed.
Interested in better understanding docking artifacts, the
false positives among the 198 top scoring compounds by
docking were visually inspected. These compounds are char-
acterized by two principal features: molecules containing
severalpolargroupswithunfulfilledcruzaininteractionsand
molecules with high internal energy (Table 1, Figure 5).
These observations reflect known liabilities of the docking
program used here, DOCK 3.5.54,
17,18 and are common
problems in the field.
24,25 The observation of groups with
manyunfilledinteractions,responsiblefor34%ofthesefalse
positives, is likely caused by the difficulty in balancing the
positiveeffectsofelectrostaticsinteractionsandtheenergetic
cost ofligand desolvation. Themost common sourceoffalse
positives,observedfor53.5%ofthetoprankingcompounds,
werehighenergyconformations.Almostallcasesinthisclass
(51%) were due to conformations of back-to-back amides in
which the torsional angle around the carbonyl-carbonyl
bond is zero and the two amide hydrogens, both bearing a
partial positive charge, point toward each other (Figure 6b).
These hydrogens interact with the backbone carbonyl from
Asp161 in cruzain, making favorable electrostatic inter-
actions with the enzyme but are unpenalized for the electro-
static cost of juxtaposing the two amide nitrogen dipoles.
High energy conformations that score well reflect the ab-
sence ofanexplicit considerationofligandinternalenergyin
the DOCK 3.5.54 scoring function. Whereas only the lowest
energy conformations of a compound are included when
building the database to be docked, molecules within a
certain energy window from the lowest energy are included
and differences in the internal energy among these confor-
mations are not taken into account at later stages in the
virtual screening. A related case was observed for 2.5% of
false positives, which contained highly flexible substituents.
These reflect the absence of a penalty for entropic losses
upon binding to the protein.
Comparing Docking with Ligand-Based Screening. A goal
of this project was to discover novel chemotypes to inhibit
cruzain. A question that emerged in the review and revision
of this project was how novel the compounds discovered
were and how efficient the structure-based and HTS mod-
alities were. To investigate this question, we used the ligand-
based similarity ensemble approach (SEA),
26 which had
shown some success in identifying new ligands for well-
annotated targets, to screen each compound in the MLSMR
Figure 3. Progression of the number of HTS hits and docking
enrichment factors at different stages of mechanistic follow up.
The enrichment factor was calculated at the top 0.1% of the
database(198compounds)andrepresentstheratiobetweentheper-
centage of ligands ranked among these compounds and the percen-
tage which would be expected to be found by random chance
(0.1%).4898 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 Ferreira et al.
library against a set of 128 known cruzain inhibitors. Com-
pounds were screened by 2D chemical similarity based on
theirECFP4andDaylightfingerprints.ApplyinganE-value
thresholdof10
-10,961hitswereobtainedinformercaseand
154 hits in the later. Whereas some irreversible and likely
nonspecific inhibitors were identified, none of the cruzain
competitive inhibitors discoveredin thisstudywas identified
bythisligand-basedapproach,evenifalessstringentE-value
Figure 4. Predicted binding modes for competitive cruzain inhibitors. Best scoring pose of highest ranking compound in each cluster shown.
(a) compound 1, rank 6 (out of 197861), cluster 1; (b) 4, rank 153; (c) 5, rank 173; (d) 15, cluster 2, rank 7560; (e) 17, cluster 31, rank 31359.
Cruzain surface shown in gray. Active site cysteine 25 and residues involved in hydrogen bond interactions shown in sticks. Dashed lines
represent hydrogen bonds. Protein carbon atoms colored gray and small molecules carbon atoms colored green. Oxygen, nitrogen, and sulfur
colored red, blue, and yellow, respectively. Chlorine and fluorine colored magenta and cyan, respectively. Figures prepared with Pymol.
59.
Figure 5. Main sources of virtual screening false positives. Predicted poses for top ranking false positives: (a) rank 1, illustrating presence of
unfulfilled polar interactions, (b) rank 3, representing high energy conformations. Cruzain surface shown in gray. Active site cysteine 25 and
residues involved in hydrogen bond interactions shown in sticks. Dashed lines represent hydrogen bonds, waters are shown as red spheres.
Protein carbon atomscoloredgray, andsmall molecules carbonatoms coloredgreen. Oxygen, nitrogen,sulfur,and chlorine coloredred, blue,
yellow, and magenta, respectively. Figures prepared with Pymol.
59.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 4899
threshold of 10
-1 was used. The top hits obtained were
peptidic inhibitors (Figure 6) and in some cases contained
reactivemoieties,asexpectedbasedonthepropertiesofmost
knowncruzaininhibitors.Theseresultssupporttheviewthat
the inhibitors discovered by docking and qHTS were sub-
stantially different from known cruzain inhibitors.
Discovery of a Class of Cruzain Substrates among Compe-
titive Compounds. To understand the molecular bases of
recognition, we pursued cocrystallization of cruzain with
the noncovalent competitive inhibitors. Cruzain was cocrys-
tallized with one compound from each class of competitive
inhibitors (compounds 4, 5, 11, 27, and 29), using standard
conditions.
21 Crystals diffracted well, often to ultrahigh or
near-ultrahigh resolution (1.0-1.3 A ˚ ), and the structures
weredetermined.However,electrondensityformostligands
was poor, and with exception of compound 27 (cluster 2) it
was not possible to resolve ligand coordinates unambigu-
ously. Althoughpoorelectrondensitymight beexplained by
poorsolubilityorhighflexibilityofcompounds,thepresence
oflabilegroups,especiallyestersincluster1andcompound4,
prompted us to investigate if compounds were degraded
in the crystallization buffer (2 mM Bis-Tris pH 5.8). To this
end, we applied liquid chromatography coupled to mass
spectrometry (LC/MS). Most compounds were stable over
several hours in the presence or absence of cruzain, however
we observed enzyme-catalyzed degradation of compound 11
in the presence of 100 nM cruzain (Figure 7, Supporting
Information Figure 3). While the intact compound was still
observed in solution even after one day of incubation in the
absence of cruzain, in the presence of enzyme it was absent
after a 40 min incubation, indicating that cleavage of 11 was
enzyme catalyzed. Further evidence of hydrolysis was ob-
tained by measuring time-dependence of cruzain inhibition
by two compounds from cluster 1, 11 and 8, which showed
the lowest IC50 against cruzain within this cluster. We
compared percentages of cruzain activity after incubation
with1μMof8or10μMof11from0to240min(Supporting
Information Figure 3). A clear time-dependent effect on the
fraction of active cruzain was observed in the presence of
enzyme.
Before learning of the substrate properties of this chemo-
type, we investigated a limited SAR series around the
benzamidoacetate series (exemplified by compounds 8 and 11).
Several analogues were prepared and evaluated for potency
(Supporting Information Table S5). The most active
of these new compounds inhibited cruzain with an IC50 of
30 nM, 8-fold better than that of the best HTS hit in this
series, 11 (IC50 = 260 nM). Whereas this suggests that this
series is optimizable, we note that even in these more potent,
low nanomolarinhibitors,replacementoftheesterfunction-
ality with an amide moiety resulted in complete loss of
activity as did other hydrolytically stable ester isosteres such
as oxadiazole and thiadiazole analogues (Supporting Infor-
mation Figure 4). This suggests that even these more potent
ligands are also best thought of as tight-binding substrates
for the enzyme.
Compounds 4 and 5, which are not from cluster 1, were
alsoevaluatedforstabilityinthepresenceofenzymebyboth
LC/MSandthetime-dependenceassaybutdidnotbehaveas
substrates (Supporting Information Figure 5). Over a four-
hour period, or even after a day in the case of compound 5,
these compounds were stable by LC/MS in the presence of
100 nM cruzain. They also inhibited cruzain at similar levels
regardless of incubation time.
Crystal Structure of Cruzain/27 Complex. A structure of
the cruzain complex with compound 27, a docking false
negative, was solved to near ultrahigh resolution (1.28 A ˚ ,
Table 4). Most residues in the active site are observed in
conformations similar to the ones present in the cruzain
structure used for docking.
15 The most significant changes
areaflipinGln159anddoubleconformationofthecatalytic
Cys25 (Supporting Information Figure 6). The lower occu-
pancy Cys25 conformation (approximately 30%) is cova-
lently modified by S-methyl methanethiosulfonate, a cova-
lent reversible cruzain inhibitor used in the purification of
this enzyme and removed prior to the crystallography. The
higher occupancy Cys25 conformation is unmodified. Also,
small differences are observed for residues forming the S2
pocket, such as Glu208, Leu67, and Leu160, which move
toward the ligand.
Figure 7. Identified cruzain substrate. Structure of compound 11,
identified as a cruzain substrate through LC/MS and biochemical
assays, and highly ranked by docking. Predicted cleavage site
indicated (wavy line).
Figure 6. Chemical structures of representatives of top scaffolds identified by ligand-based virtual screening. No competitive inhibitors were
among the hits identified by this method.4900 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 Ferreira et al.
Unambiguous electron density was obtained for the in-
hibitor (Figure 8). The amide group in 27 binds between the
S1 and S2 pockets, making interactions similar to those
previously observed for covalent cruzain inhibitors,
23
although the X-ray structure confirms the lack of covalent
attachment. The amide nitrogen hydrogen bonds to the
carbonyl in Asp161 (distance 2.99 A ˚ ), whereas the carbonyl
hydrogenbondstothebackbonenitrogeninGly66(distance
3.04 A ˚ ). The bromo-phenyl ring occupies the S2 pocket of
cruzain, and the ester makes a dipole-dipole interaction
with the backbone nitrogen in His162 (3.19 A ˚ ). The benzi-
midazole ring is mostly solvent exposed, and its nitrogens
hydrogen-bond to waters 226 and 218 (3.00 and 2.55 A ˚ ,
respectively). In the docking prediction, the bromo-phenyl
ring occupies the S2 pocket as experimentally observed,
although the ring is flipped by approximately 180  and the
amidenitrogenhydrogenbondstoAsp161carbonyl(2.85A ˚ ),
also as observed by crystallography (Figure 8). Past this
point, the overlap with the crystallographic pose becomes
poor because the benzimidazole ring position is in a com-
pletely different region of the active site.
Investigation of Causes of Poor Ranking of Compound 27
byDOCK.Uponobtainingthestructureofcruzainboundto
27, we were interested to know why DOCK failed to predict
the correct binding mode for this compound. Whereas the
specific reasons for virtual screening failure are hard to
determine in a complex binding site, it is usually possible to
divide docking problems into inadequate sampling andpoor
scoring.
Problems in sampling might owe to the absence of the
relevant conformation in the database or to inadequate
sampling of the right orientation by docking. To investigate
if the crystallographic conformation was docked, all 600
conformations of 27 present in the database were rigidly
docked in multiple orientations and the rmsd between the
observed binding mode and the best scoring pose for each
conformation was calculated. Several conformations within
a2A ˚ cutofffromthecrystallographicwereobserved,withrmsd
values as low as 1.4 A ˚ (Supporting Information Figure 7).
Even though the torsional angle around the methylene-
carbonyl bond in this conformation differed from the crys-
tallographic one, most of the compound overlaps well with
Figure 8. Comparison between docking pose and crystallographic geometry of compound 27. (a) Stereo view of unbiased electron density
(Fo - Fc countoured at 3σ) from cruzain/27 complex structure determined to 1.28 A ˚ . (b) Key interactions between compound 27 and cruzain.
Dashed lines represent hydrogen bonds (orange) or dipole-dipole interactions (green), waters are shown as red spheres. (c) Superposition of
docking pose and crystallographic geometry. Carbon atoms colored gray for cruzain, cyan for crystallographic pose, and green in DOCK
predicted pose. Oxygen, nitrogen, sulfur, and bromine colored red, blue, yellow, and orange, respectively. Figures prepared with Pymol.
59.
Table 4. Data Collection and Refinement Statistics for Cruzain/27
Complex
Data Collection
space group P6522
cell dimensions
a, b, c (A ˚ ) 82.98, 82.98, 101.73
R, β, γ (deg) 90, 90, 120
resolution (A ˚ ) 1.28(1.33-1.28)
a
Rsym or Rmerge 9.2(18.6)
I/σI 78.0(29.3)
completeness (%) 99.9(100.0)
redundancy 11.5(11.0)
Refinement
resolution (A ˚ ) 41.46 to 1.28
no. reflns 59354
Rwork/Rfree 0.115/0.144 (0.078/0.132)
no. atoms
protein 1,559
ligand/ion 163
water 314
B-factors
protein 8.5
ligand/ion 12.8
water 25.7
rms deviations
bond lengths (A ˚ ) 0.013
bond angles (deg) 1.491
aValues in parentheses are for highest-resolution shell.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 4901
the crystallographic pose, capturing the interactions ob-
served experimentally. This result suggested that poor rank-
ing of this compound was not due to undersampling.
Next,weinvestigatedwhetherthecrystallographicposeof
27 would score well in the energy potential maps used for
docking. DOCK 3.5.54 uses three terms in its scoring func-
tion: van der Waals interactions, electrostatic interactions,
andapenaltyforliganddesolvation
18,27,28(M.Mysingerand
B.K.S., unpublished). For any docked orientation, the con-
tribution of each atom for each term in the scoring function
can be evaluated. In the energy potential maps calculated
from the conformation of cruzain used in the docking, the
crystallographic geometry of 27 scores poorly at -8.5 kcal/
mol and would have ranked 180479 out of the 197861
molecules docked (DOCK’s energy scores are typically far
offset from binding affinities, as was the case here). This is
much less favorable than the energy scores obtained for the
best scoring pose of this compound by docking (-35.5, rank
28521). The difference between the scores of these two
conformations is due to much less favorable scores for the
crystallographic conformation both in the van der Waals
term(-8.4vs-22.2forthedockedconformation)andinthe
balance between electrostatic score and ligand desolvation
(-0.1 vs -13.3 Supporting Information Table S6). We then
evaluated how 27 scored in grids prepared using the cruzain/
27 complex structure determined here but otherwise follow-
ing the same protocol in grids preparation. The score of the
crystallographic pose improved, and the gap between scores
of crystallographic pose, -17.6 kcal/mol, and the best scor-
ing pose by DOCK, -26.7 kcal/mol, is reduced. This
improvement is due to more favorable van der Waals inter-
actions, suggesting that even though the conformational
changes observed for residues in the cruzain active site are
small, considering this flexibility would substantially impact
the scoring of this compound.
Discussion
We may now tender preliminary answers to the questions
that motivated this study. The dominant source of false
positives in this screen, as in earlier ones,
10 remains colloidal
aggregation, contributing 88% of the initial screening hits in
the cruzain qHTS. Contributions from fluorescence interfer-
ence and promiscuous covalent inhibition, although still sub-
stantial at 3% and 5% of the initial hits, respectively, were
much less. As in earlier studies,
10 the results support response
to detergent as a fast initial screen to identify colloidal
aggregators. Whereas this test does not identify all aggrega-
tors, it does identify over 95% of them, and as previously it
appears more reliable even than properties such as high Hill
slopes,
29whichonlyidentifyabout50%ofaggregators,
13also
consistentwithpreviousobservations.
10Thisstudyisalsoone
ofthefew,perhapsonly,toallowacomprehensiveanalysisof
docking false positives, and here the results were perhaps less
expected.Thelargestsinglegroupofthesefalsepositivesowed
to the adoption of high-energy ligand conformations that fit
the cruzain structure well but, without being grossly wrong,
are energetically inaccessible to the small molecules. Corre-
spondingly, testing of the entire library reveals docking false
negatives, which X-ray crystallography suggests derive from
scoring problems, partially due to small conformational
changes in the protein upon ligand binding. Notwithstanding
these problems, this study has identified five new, competitive
familiesofinhibitorsforcruzain,fourofwhicharenoncovalent
and reversible, suggesting that such inhibitors can be found
despite the dominance of covalent inhibitors for this and
related thiol proteases. Perhaps most generally, if most tenta-
tively, this study supports the idea that docking and high-
throughput screens are complementary and may be usefully
combined, with the docking providing orthogonal structural
supportfortheprioritizationofinterestingscreening“hits”to
follow up. We take each of these points in turn.
Owing to the high frequency of false positives in HTS and
docking,
30-34 discovering true inhibitors from among initial
screening hits requires extensive counter-screening and me-
chanistic investigation. The observations afforded by qHTS,
where every compound was tested in seven point dose-
response, are of relatively high quality for the field, and even
so, only 1% of initial hits were noncovalent, competitive
inhibitors. Whereas colloidal aggregation remains by far the
dominant form of artifact,
35-37 again contributing approxi-
mately 90% of the hits,
4,10,13 this biophysical mechanism has
the virtue of being easily controlled for, at least for the
majorityofaggregators,that are detergentsensitive. Buteven
among the active molecules that remain after discarding the
detergent-sensitiveaggregators, over 90% stillact by undesir-
ablemechanisms.Thisisconsistentwiththeideathatthemost
difficult part of a screening project comes after the screen
has been performed and one is left with a large number of
potentially interesting molecules, most of which are mis-
leading, through which one must carefully sift by detailed
experiment. Analyzing the direct, unfiltered results of HTS
campaigns,suchasonemightoftenfindinpublicrepositories,
might lead one quickly astray.
Among virtual screening top hits, approximately 90%
could be explained by two main sources of false positives.
Overhalfoftheseartifactsresultfromfailingtopenalizehigh-
energy compound conformations in the docking score. This
supports the need to consider an internal energy term for
conformations docked and the loss of degrees of freedom for
the ligand, as previously demonstrated in a study of HIV
reverse-transcriptaseinhibitors.
25,38Anotherthirdofthefalse
positives owes to high molecular weight compounds contain-
ing unfulfilled polar groups. These compounds likely score
well due to difficulties in balancing the favorable van der
Waals and electrostatic interactions with the protein and the
unfavorable desolvation energy involved in the formation of
the complex.
Thedeterminationofthecrystalstructureofthecruzain/27
complex illustrates one of a docking false negative at atomic
resolution.Withthestructuredetermined,itseemsclearthata
contributiontoits lowranking inthe docking screenis thatin
itsboundformcruzainmakessmallbutimportantconforma-
tional accommodations that improve its overall complemen-
tarity to the inhibitor. This reinforces the importance of
considering proteinflexibilityinstructure-based screens,even
for relatively rigid active sites, like that of cruzain. This
remains the subject of intense research,
39-42 and it is in some
senses an expected problem. Less anticipated was the adop-
tion of a conformation where that the benzimidazole ring of
27 climbs out of the active site. The complementarity here,
also missed in the docking, is with ordered water molecules,
the use of which in docking is also being pursued.
43-46 More
broadly, whereas previous combinations of virtual and ex-
perimental screening have led to the identification of hits,
6-9
illustrating some of the strengths of docking, reporting the
rate of docking false negatives allows a fair evaluation of
virtualscreeningalsofromitsfailures.Toourknowledge,this4902 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 Ferreira et al.
has been previously reported in only one study
6 and without
structural information on the binding mode of the false
negatives.
An encouraging result to emerge from this study was the
discoveryoffivenewscaffoldsofcompetitiveinhibitorsofthis
key parasitic target, with Ki values ranging from 65 nM to
6 μM. Whereas several classes of inhibitors for this enzyme
have been previously described, almost all are peptidic cova-
lent agents. Among the classes discovered here, some com-
pounds are more peptidic, and in the case of cluster 1 were
later found to be cruzain substrates. Other molecules, in
clusters 2 and 31, present novel nonpeptidic scaffolds. These
compounds could serve as starting points for medicinal
chemistry optimization, especially clusters 2 and 31, which
containmostlylead-like
47compounds.Inthecaseofcluster2,
thehighresolutioncrystalstructurereportedherecanprovide
additional guidance for a structure-based design effort. Con-
sistentwiththenoveltyofthesechemotypes,noneofthesefive
scaffolds were identified by an inference-rooted ligand-based
screen, which instead suggested chemotypes that closely re-
sembled previously known ligands and that, if anything,
would act in a covalent and irreversible manner (Figure 6).
Because most known cruzain inhibitors used in the reference
set were high molecular weight, covalent, peptidic inhibitors,
this is unsurprising. Of course, this reflects the results of only
oneligand-basedmethod,anditmaywellbethatanothersuch
technique would have found the true ligands revealed here by
docking and qHTS. Still, the failure to find the true nonco-
valent ligands by an inference-based approach supports the
novelty of the chemotypes discovered here.
Perhaps the most ambitious goal of this study was to
investigate how structure-based screening can prioritize true
actives from HTS and the origins and frequency of false
positives and false negatives in this approach. Even with all
of the codicils, caveats, and liabilities in docking, half of
the scaffolds that turned out to be noncovalent, competitive
inhibitors identified by HTS, in addition to the class of
substrates identified here, were among the top 0.1% of the
collection prioritized by docking. Indeed, two of the five
classes of ligands were only prioritized for follow-up based
on their docking rankings; because these compounds repre-
sentedonlysmallclusters,theyhadlittleSARandsowerenot
prioritized for further investigation as part of the HTS work-
flow. Clearly it was combination of activity in the qHTS and
high docking ranking that identified these compounds; we do
not pretendthattheserepresentscreening “false negatives”as
this term is usually understood. More broadly, had we relied
on docking to prioritize compounds to be tested experimen-
tally, rather than pursuing the parallel tracks that we did, we
would have screened 1000 times fewer compounds but found
60%ofthecompetitivescaffolds.Hadwescreenedthetop5%
docking ranked library, only one inhibitor class would have
been missed. This agrees with earlier work by Keseru and
colleagues, where the top ranking 1% of docked molecules
resembledfourofthesix scaffoldsfoundbyHTS,
6andwitha
β-lactamase study from our own groups, where all of the true
noncovalent inhibitors from a virtual screening and HTS
were identified by docking alone; both of these studies repre-
sented much smaller screens than that undertaken here.
4 This
work supports the potential for using structure-based virtual
screening in the prioritization of compounds either to be
screened by HTS or, as is our preference, to be pursued after
the HTS is prosecuted.
Experimental Section
Database Preparation. The 197861 compounds present in the
MLSMR database were submitted to standard preparation
protocols for addition to the ZINC database,
16 as recently
described.
4 After removal of duplicates, 195177 unique mole-
culesweredetected,outofwhich187693weresuccessfullyadded
tothedatabase.Thediscrepancyof7484moleculesnotaddedto
the database is due to 531 compounds filtered due to egregious
violation (such as molecular weight over 600 g/mol, unaccep-
table atom, or more than 20 chiral centers), 3151 molecules that
were not handled correctly by our automatic database prepara-
tion procedure and 3802 not loaded for other reasons, such as
absence of polar atoms.
Virtual Screening. The compound library was virtually
screened using DOCK 3.5.54. Docking was performed against
PDB structure 1AIM.
15 This structure was selected after a
comparison of the 13 structures of cruzain in complex with
inhibitors at that point available in the PDB. Only very small
differences were observed for the active site residues conforma-
tions, except for Glu208, which is highly flexible and can be
either exposed to solvent or rotated toward the cruzain S2
pocket.
48 In previous docking studies with cruzain, we were
successfulinidentifyinghitsiftheGlu208wasrepresentedinthe
conformationinwhichitisrotatedtowardtheS2pocket,
49such
as observed in 1AIM (conformation A), while no hits were
found in docking to 1ME3 structure, in which the Glu208 side
chain is rotated toward solvent. In this study, we again con-
sideredbothpossibilitiesforGlu208conformationbutobtained
better enrichments for structure 1AIM. Therefore, the results
obtained with this structure were chosen for the comparison
with HTS.
No waters seemed to be conserved among the available
structures and therefore prior to docking all waters were re-
moved.Hydrogenswereaddedtostandardpositions.Matching
spheres were generated based on atomic positions of 10 inhibi-
tors from published structures and later modified to be concen-
trated in the cruzain S2 pocket.
To improve hydrogen bonding complementarity and based
on analysis of common hydrogen bonds present in 13 cruzain
structures available in the Protein Data Bank (as of July 2007),
partial atomic charges were increased by 0.4 in the amide side
chain of glutamine 19 (Oε1 and HNε1, HNε2, with the positive
charge divided between the two hydrogens and increased by 0.2
in each), in polar atoms of cysteine 25 (O, Sγ, HN, and HSγ), in
the amide backbone of aspartate 161 (O and HN), and in polar
atoms of glycine 66 (O and HN). This is consistent with similar
treatment in earlier prospective docking campaigns from our
lab.
4,50 Sampling parameters used were matching tolerance of
1.2 A ˚ and bin sizes of 0.4 A ˚ for both ligand and receptor, with
an overlap of 0.3 A ˚ . To accelerate calculations in DOCK,
energy potential grids were precalculated using the programs
CHEMGRID
28 and Delphi.
51 Multiple conformations and
orientations of each ligand were scored based on van der Waals
and electrostatic interactions with a penalty for ligand desolva-
tion (M. Mysinger, A.B.D., B.K.S., unpublished).
4,50 The best
scoring conformation of each compound was used for ranking
the database.
Docking of Compound 27. The 600 conformations of 27
generated by OMEGA (OpenEye Scientific Software, Santa
Fe, NM) and used for docking the library were rigidly docked
tocruzain,bothintheoriginalgridsandingridsgeneratedusing
cruzain coordinates from the determined structure in complex
with this compound. Sampling parameters used for single mode
runswerematchingtoleranceof1.2A ˚ ,binsizesof0.4A ˚ ,andbin
overlaps of 0.2 A ˚ . Root mean square deviations (rmsd) were
calculatedbetweeneachgeneratedposeandthecrystallographic
pose of compound 27.
The program scoreopt was used to investigate detailed
scoring for the crystallographic pose of compound 27 in bothArticle Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 4903
grids used. Scoreopt allows the calculation of electrostatic and
van der Waals contributions and the desolvation penalty for
each atom in the ligand. The scores for each term in the
DOCK3.5.54 scoring function were compared to those for the
best ranking pose obtained by the program in the same grids.
Papain Counter-Screen. The 921 detergent-resistant, non-
fluorescent top hits obtained from qHTS
13 were clustered based
on their 2D structures using Leadscope’s structural fingerprint
and a Tanimoto coefficient cutoff of 0.7. A total of 149 clusters
were obtained, 70 of them containing four or more active
compounds. These were further filtered based on potency cut-
offs. A total of 199 compounds, including active and inactive
members of a filtered set of 47 clusters, plus 35 singletons, were
screenedinparallelagainstcruzainandpapain.Eachcompound
was tested in seven different concentrations against each en-
zyme. Screening against papain was performed following the
protocol and reaction conditions previously described for
cruzain
13 with the following two changes: (1) cysteine, added
to the buffer at 5 mM final concentration, was used to maintain
papain activity instead of the dithiothreitol employed in the
cruzainassayand(2)papainwasusedatafinalconcentrationof
12 nM in order to obtain adequate assay signal.
Cruzain Inhibition Assays. Cruzain activity was measured by
monitoringthecleavageofthefluorogenicsubstrateZ-Phe-Arg-
aminomethylcoumarin (Z-FR-AMC). All cruzain assays were
performedinsodiumacetate0.1MpH5.5andinthepresenceof
5 mM dithiothreitol (DTT). The final concentration of cruzain
was 0.4nM, andthe substrate concentration was2.5 μM( Km =
2 μM), except for Ki determination, when the Z-FR-AMC
varied from 0.31 to 20 μM in 2-fold increments. Assays were
conducted in presence of 0.01% Triton X-100, except for
evaluation of detergent-sensitivity, when inhibition was com-
pared in 0, 0.01 and 0.1% Triton. Assays were followed for
5 min, and activity was calculated based on initial rates.
For evaluation of time-dependent inhibition, percentages of
enzyme inhibition by a compound with or without preincuba-
tion with enzyme for 10 min were compared. During the
preincubation step,cruzainandcompoundconcentrationswere
10-fold higher than in the final assay. In assays performed in
the absence of detergent, compounds were always preincubated
with cruzain for 5 min to allow small molecule aggregate for-
mation because this was the purpose of these nondetergent
assays. Investigation of other mechanisms were typically con-
ducted in the presence of detergent, and here there was no
preincubation with enzyme unless compound inhibition was
known to be time-dependent. For these known time-dependent
inhibitors,5minincubationwasperformedtoallowdiscrimina-
tion between time-dependence and detergent-sensitivity. We
note that in the initial qHTS, the incubation time with and
without detergent was the same.
13
To determine if cruzain inhibitors were competitive, each
compound was tested in at least four concentrations (variable
depending on IC50 against cruzain) and seven concentrations of
Z-FR-AMC (0.31-20 μM, in 2-fold increments). Data was
analyzed with Prism 4 (GraphPad), and Ki values were deter-
mined from Lineweaver-Burk and Dixon plots.
AmpC β-Lactamase Inhibition. AmpC activity was based on
rates of cleavage of the substrate CENTA, measured by mon-
itoringabsorbanceat405nmfor3minandwascalculatedbased
on initial rates. Assays were performed at potassium phosphate
50 mM, pH 7.0, with final concentrations of 1 nM enzyme and
100 μM substrate (Km =4 8μM). All compounds were tested in
theabsenceofTritonX-100andinthepresenceof0.01%Triton
X-100,andAmpCinhibitionrateswerecompared.Intheassays
in the absence of Triton X-100, the compounds were preincu-
bated with enzyme for 5 min before addition of substrate,
whereas there was no preincubation step in the assays in the
presence of Triton.
Cruzain Expression, Purification, And Crystallography. Cruzain
was expressed and purified in a modified version (Lee, Balouch,
and Craik, unpublished results) of a previously published pro-
tocol,
52 activated and purified as recently described.
21 Active cru-
zain was inhibited with S-methyl methanethiosulfonate (MMTS),
a covalent reversible inhibitor, to prevent self-degradation.
MMTS inhibited cruzain was concentrated to 1 mg/mL in
2 mM bis tris buffer pH 5.8. 5 mM DTT was added to reverse
MMTS inhibition, followed by addition of compound 11. The
solution was then concentrated down to 7.5 mg/mL. Crystals
were obtained by hanging drop method in a previously de-
scribed crystallization condition, 0.1 M Tris pH 8.5, 2.0 M
NH4H2PO4;
212-4μLdropswithvariousprotein:motherliquor
ratios (1:1, 1.5:1, 2:1) were set up and seeded with previously
obtained crystals. Before cryocooling, crystals were soaked for
onedayin200mMDTTandfor1hina1.4mMsolutionof27in
mother liquour. Crystals were cryocooled in a 25% solution of
ethylene glycol in mother liquor containing 1.4 mM 27. Similar
protocols were conducted in cocrystallizations of cruzain with
compounds 11, 4, 5, and 29.
Data collection was performed in frozen crystals in beamline
8.3.1 at the Advanced Light Source (ALS, Lawrence Berkeley
Laboratory, CA), using ELVES
53 to determine the data collec-
tion strategy. For the cruzain/27 complex, 200 frames were
collected, with 0.5 s exposure and 0.5  oscillations between
frames. Reflections were indexed and integrated using Mosflm
and scaled using SCALA.
54 The structure was solved by molec-
ular replacement using Phaser, with PDB structure 3I06 as the
template. Data refinement was performed using Phenix,
55 and
models were built using Coot.
56 In the final model, 84.2% of
residues were in the most favored regions in the Ramachandran
plot, 15.3% were in additional allowed regions and 0.5% in
disfavored regions. PDB accession code 3KKU.
Liquid Chromatography/Mass Spectrometry (LC/MS). Solu-
tions of compounds 11, 4, and 5 were prepared in 2 mM Bis Tris
pH 5.8, in the presence or absence of 100 nM cruzain. Solutions
wereexaminedbyLC/MSatseveraltimepoints(from30minto
24 h) to investigate if these compounds were degraded over time
and if degradation was catalyzed by cruzain. LC/MS was
conductedonaWatersMicromassZQinESIþmode,equipped
with a Waters 2996 photodiode array detector and a Waters
Alliance 2795 separations module. Compounds were eluted
through an analytical Xterra C-18 column, using a methanol
(0.2% formic acid)/water (0.2% formic acid) system, with a
lineargradientfrom5to95%waterin6minandaflowrateof1
mL/min. Elution was monitored at 254 nm.
Compound Purity. As previously described,
13 all compounds
in the MLSMR library were purchased and their purity was
certified by the corresponding vendors. Briefly, the entire screen-
inglibrary(GalapagosBiofocusDPI,SouthSanFrancisco,CA)
wassubjectedtopurityanalysisbeforeplatingbyusinganeight-
channelMUXhigh-throughputparallelchromatographicsystem
(Micromass Ltd., Manchester, UK, and Waters, Milford, MA)
and separating the sample on Phenomenex Gemini 5 um C18
column (2 mm   50 mm). Compounds used in the follow up
experiments were reanalyzed for purity via liquid chromatogra-
phy-massspectrometry(LCMS).Allcompoundspassedpurity
criteria (g95%).Forfollow upassaysatUCSF, compounds26,
44, and 45 were resourced from the NCGC. All other com-
pounds were purchased and that their purity certified as at least
90% (frequently >95%) by their vendors. Among the com-
pounds confirmed as competitive inhibitors, 4, 5, and 8 were
purchased from Enamine, with at least 90% purity assured by
the company. Compounds 27 and 29 were purchased from
ChemBridgeandIBScreen,respectively,andbothwerecertified
>95% pure; for compound 27, the 1.28 A ˚ X-ray structure, in
complex with the cruzain, was consistent with its reported
structure.
Ligand-Based Virtual Screening. We screened the MLSMR
library against the cruzain reference set using the similarity
ensemble approach (SEA).
26 For pairwise molecule compari-
sons, we used Tanimoto coefficients with both 1024-bit folded4904 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 13 Ferreira et al.
Scitegic ECFP_4 topological fingerprints and 2048-bit folded
Daylight fingerprints, each in separate SEA runs, as previously
described.
26,57,58 The reference set was composed of 128 cruzain
inhibitors. Of those, we obtained 118 unique cruzain inhibitors
with Ki e 1 uM from the ChEMBL_02 database (http://www.
ebi.ac.uk/chembldb/) and 10 inhibitors with IC50 < 1 uM from
the Collaborative Drug Discovery database.
5 We processed
and canonicalized all cruzain inhibitor and all 239762 unique
MLSMR1 compound structures as previously described.
26,57,58
We then compared all hits with E-values e1   10
-1 to the list of
146 competitive cruzain inhibitors. We chose a particularly
weak E-value threshold here to demonstrate that any competi-
tive cruzain inhibitors not found by this ligand-based virtual
screen were missed despite a highly permissive search.
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parison of DOCK scores for crystallographic and DOCK poses
of compound 27. Synthesis and in vitro activity of analogues of
compound 11. This material is available free of charge via the
Internet at http://pubs.acs.org.
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